XXXX treatment in a population of adults with @entity1032 .

@entity1 @entity1088 @entity1032 @entity162 @entity410 @entity4750 @entity146 @entity73 @entity914 @entity3028 @entity3626 @entity161 @entity1142
BACKGROUND: There is a paucity of data on the use of @entity1088 in @entity1 with @entity1032 and comorbid @entity146 . The authors describe their recent clinical experience using @entity1088 in treatment-refractory @entity1 with @entity1032 and severe @entity146 . METHOD: A retrospective review was performed on the records of all @entity1 admitted to a university-affiliated, specialized inpatient psychiatry service who were selected for @entity1088 therapy from March 1994 through December 1997 (N = 33). @entity1 had DSM-IV diagnoses of @entity161 , @entity914 , @entity162 , @entity4750 , or @entity914 NOS and were considered treatment resistant. All had deficits in functioning well beyond those expected for their degree of @entity73 and @entity3626 . RESULTS: Of 33 initial @entity1 , 26 remained on @entity1088 therapy for a follow-up duration of 5 to 48 months (mean = 24.8 months). Evaluation at follow-up revealed Clinical Global Impressions-Improvement (CGI-I) scores from 1 to 4 with a mean +/- SD improvement of 2.0 +/- 0.8 (much improved). The mean +/- SD rating of the CGI-Efficacy Index was 5 +/- 2.6 (decided improvement and partial remission of symptoms with no interference from side effects). The 6 @entity1 who were not maintained on @entity1088 therapy over the study period did not significantly differ from the @entity1088 group in gender, race, age, side effects, or diagnosis. One @entity1 was lost to follow-up. Side effects were mild and transient with @entity1142 being the most common (N = 10). There were no significant cardiovascular side effects and no @entity410 . No @entity1 discontinued treatment due to @entity3028 . CONCLUSION: The current investigation lends support to the conclusion that @entity1088 appears to be safe, efficacious, and well tolerated in individuals with @entity1032 and comorbid @entity146 .
